Biosimilar Naming Controversy Continues
Amid all of the recent controversy surrounding biosimilar naming, the FDA has received its first request to approve a biosimilar medicine. With that request for approval has come an inquiry from several U.S. senators to the U.S. Department of Health and Human Services asking when a formal policy will be adopted for naming biosimilar medications. Continue reading
Major Groups Calling for Biosimilar Naming Reform
With a coalition of 32 major pharmacies, health insurers, unions, and pension plans asking the FDA not to require distinct names for biosimilar medications, changes could be coming for all pharmaceutical branding efforts. Some of the larger entities supporting the change include two large unions–AFL-CIO and AFSCME; and two of the largest pharmacy benefit managers–CVS Caremark and Express Scripts.
Brandsymbol Partners with Med-ERRS to Cultivate Safe Pharmaceutical Trademarks
Charlotte, NC – July 9, 2014 – Brandsymbol, a global branding agency, has partnered with Med-ERRS, an organization that works with the healthcare industry to prevent medication errors, in order to provide world-class pharmaceutical branding and safety testing to their clients.
Brands Battle at the FIFA World Cup
With The World Cup currently in full swing, nearly every brand is attempting to leverage the world’s largest sporting event in some form or fashion, from the hilariously misinformed, to the borderline irreverent. Continue reading
New FDA Guidance
Last week the FDA released its highly anticipated draft guidance outlining new recommended best practices for trademark name development. The guidance is titled, “Best Practices in Developing Proprietary Names for Drugs.” Our partners, Med-ERRS plan to submit comments to the docket and have already Continue reading